SIGLEC8
Sialic acid-binding Ig-like lectin 8
As of the edition of 20 October 2026, SIGLEC8 (sialic acid-binding Ig-like lectin 8, UniProt Q9NYZ4) has 1 drug tested at it and 1 company on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NYZ4
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Immune system; Blood and lymph; Digestive system; Skin and connective tissue; Cancer; Eye; Inherited and neonatal
- Registered trials of its drugs
- 14
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lirentelimab | Stopped | Phase 3 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Concentra Biosciences | Route A |
The other 0 companies at SIGLEC8
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at SIGLEC8, ranked, with the facts behind eachRequest access. Nothing is shown until you do.